Vše

Co hledáte?

Vše
Projekty
Výsledky výzkumu
Subjekty

Rychlé hledání

  • Projekty podpořené TA ČR
  • Významné projekty
  • Projekty s nejvyšší státní podporou
  • Aktuálně běžící projekty

Chytré vyhledávání

  • Takto najdu konkrétní +slovo
  • Takto z výsledků -slovo zcela vynechám
  • “Takto můžu najít celou frázi”

Psychopharmacological Agents During Pregnancy and Nursing

Identifikátory výsledku

  • Kód výsledku v IS VaVaI

    <a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11120%2F21%3A43922633" target="_blank" >RIV/00216208:11120/21:43922633 - isvavai.cz</a>

  • Výsledek na webu

    <a href="https://doi.org/10.1007/978-3-319-56015-1_268-1" target="_blank" >https://doi.org/10.1007/978-3-319-56015-1_268-1</a>

  • DOI - Digital Object Identifier

    <a href="http://dx.doi.org/10.1007/978-3-319-56015-1_268-1" target="_blank" >10.1007/978-3-319-56015-1_268-1</a>

Alternativní jazyky

  • Jazyk výsledku

    angličtina

  • Název v původním jazyce

    Psychopharmacological Agents During Pregnancy and Nursing

  • Popis výsledku v původním jazyce

    Decision-making about pharmacotherapy of mental disorders during pregnancy and lactation is a source of uncertainty in clinical practice. Potentially deleterious effects of drugs on the fetus and the infant are much feared; but at the same time, negative impact of untreated mental disorder have to be taken into account. Discontinuation of long-term medication increases greatly the risk of a relapse, may worsen the course of illness, and results in poor overall outcome. Drug pharmacokinetics is markedly changed throughout the pregnancy and postpartum; thus, the dosage has to be adjusted appropriately. It should be emphasized that mental disorders alone have been associated with numerous pre-, peri-, and postnatal complications and adverse effects on the fetus and the infant. Therefore, not all negative outcomes can be attributed to the medication. All psychotropic drugs cross placental barrier and pass into the maternal milk. The risk associated with drug treatment in pregnancy depends primarily on the period of exposure, gestational age. Teratogenic potential is greatest during the first trimester, neurobehavioral effects during the exposure in the last trimester, and withdrawal and intoxication with administration prior to the delivery. The chapter reviews available data on the risks and safety of antipsychotics, antidepressants, mood stabilizers, anxiolytics, hypnotics, and other psychopharmacological agents in pregnancy and nursing.

  • Název v anglickém jazyce

    Psychopharmacological Agents During Pregnancy and Nursing

  • Popis výsledku anglicky

    Decision-making about pharmacotherapy of mental disorders during pregnancy and lactation is a source of uncertainty in clinical practice. Potentially deleterious effects of drugs on the fetus and the infant are much feared; but at the same time, negative impact of untreated mental disorder have to be taken into account. Discontinuation of long-term medication increases greatly the risk of a relapse, may worsen the course of illness, and results in poor overall outcome. Drug pharmacokinetics is markedly changed throughout the pregnancy and postpartum; thus, the dosage has to be adjusted appropriately. It should be emphasized that mental disorders alone have been associated with numerous pre-, peri-, and postnatal complications and adverse effects on the fetus and the infant. Therefore, not all negative outcomes can be attributed to the medication. All psychotropic drugs cross placental barrier and pass into the maternal milk. The risk associated with drug treatment in pregnancy depends primarily on the period of exposure, gestational age. Teratogenic potential is greatest during the first trimester, neurobehavioral effects during the exposure in the last trimester, and withdrawal and intoxication with administration prior to the delivery. The chapter reviews available data on the risks and safety of antipsychotics, antidepressants, mood stabilizers, anxiolytics, hypnotics, and other psychopharmacological agents in pregnancy and nursing.

Klasifikace

  • Druh

    C - Kapitola v odborné knize

  • CEP obor

  • OECD FORD obor

    30104 - Pharmacology and pharmacy

Návaznosti výsledku

  • Projekt

  • Návaznosti

    I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Ostatní

  • Rok uplatnění

    2021

  • Kód důvěrnosti údajů

    S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Údaje specifické pro druh výsledku

  • Název knihy nebo sborníku

    NeuroPsychopharmacotherapy

  • ISBN

    978-3-319-56015-1

  • Počet stran výsledku

    27

  • Strana od-do

    1-27

  • Počet stran knihy

    754

  • Název nakladatele

    Springer

  • Místo vydání

    Cham

  • Kód UT WoS kapitoly